DMYDY

Diamyd Medical AB

 
Sponsored ADR (1 ADS : 1 Ordinary)
PAL: BNY Mellon OTCQX International
Contact Info
  • Karlavagen 108
  • Stockholm SE-115 26
  • Sweden


Update Company Info
Business Description

Diamyd Medical's lead drug candidate, Diamyd, is designed for treatment for both Type I (end of Phase II) and LADA Type 2 diabetes (Phase II). Other developments include a proprietary Nerve Targeted Drug Delivery System to deliver genes coding for the GAD or Enkephalin to treat diabetes pain and neuropathy (pre-clinical phase).

 
Financial Reporting/Disclosure
Reporting Status International Reporting: OMX Nordic Exchange Stockholm
Audited Financials Audited
Latest Report Apr 04, 2012 Semi-Annual Report
Regulatory Agency Not Available
CIK 0001344485
Fiscal Year End 8/31
OTC Market Tier OTCQX International
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Sweden
Year of Inc. 1996
Employees Not Available
Company Officers
Peter Zerhouni President, CEO
Darren Wolfe President
Anna Styrud CFO
Erika Hillborg Director of Development
Company Directors
Anders Essen-Moller Chairman
Henrik Bonde
Maria-Teresa Essen-Moller
Lars Jonsson
Sam Lindgren
Goran Pettersson
Service Providers
DAD/PAL
BNY Mellon
101 Barclay Street
22nd Floor
New York, NY, 10286
United States

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
DMYDY Security Details Other Company Securities
Share Structure
Market Value1 $43,337,140 a/o May 22, 2012
Shares Outstanding 28,141,000 a/o Apr 04, 2012
Float 9,115,807 a/o Dec 29, 2006
Authorized Shares Not Available
Par Value No Par Value
Shareholders
Shareholders of Record Not Available
Non US Stock Exchange Listing
DIAMA - OMX Nordic Exchange Stockholm - Qualified
Short Selling Data
Short Interest 4,550 (20.27%)
Apr 30, 2012
Significant Failures to Deliver No
Transfer Agent(s)
BNY Mellon

1Market Value calculated only for respective security